At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Director operating in the Pharmaceutical space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
_______
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Jay Bergeron
Director of Pfizer
Jay Bergeron is Director, Translational and Bioinformatics, at Pfizer and responsible for informatics support for Clinical Research and Precision Medicine.
Follow Jay Bergeron:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Julia Brosnan
Director, External Collaborations and Scientific Alliances of Pfizer
Follow Julia Brosnan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
George Bashirians
Director, Diagnostics Lead of Pfizer
Follow George Bashirians:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Amir Zur
Sr. Director, Head of Products of Digital Health of Teva Pharmaceutical Industries
Amir Zur is a Sr. Director, Head of Products of Digital Health in Teva Pharmaceuticals, Mr. Zur leads the digital products roadmap, development life-cycle and quality to build Drug-Device Combination and Medical Device products to improve outcomes and treatments to patients. Previously at Teva, he led the teams who built a novel innovative product from scratch and established digital foundations, processes and transformation in the company. The product was recently approved by the FDA as the first of its kind in respiratory and in the entire Health industry. During his career Amir held vast leadership roles as an executive manager for more than 20 years in the digital industry both global large and small companies.
Follow Amir Zur:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Emma Wright
Senior Director, Manufacturing of Dicerna Pharmaceuticals
Follow Emma Wright:
About Dicerna Pharmaceuticals: Dicerna Pharmaceuticals is a biotechnology company with a focus on the development of innovative treatments for rare inherited diseases.
Andreas Bender
Non Executive Director of PharmEnable
Andreas Bender is a Lecturer for Molecular Informatics with the Centre for Molecular Informatics at the University of Cambridge. Until April 2010 he was an Assistant Professor for Cheminformatics and Pharmaceutical IT with the Leiden / Amsterdam Center for Drug Research and Head of the Pharma-IT Platform at Leiden University. In his work, he is involved with the analysis of various kinds of bioactivity data and the generation of property prediction models, mainly for small molecules.
Follow Andreas Bender:
About NUVISAN GmbH, PharmEnable, University of Cambridge: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Eric Boutin
Managing Director of dRx Capital
Eric Boutin was Founder | CEO of Evolve, acquired by HubSpot (NYSE: HUBS). He was Founder | CEO of Good Start Genetics, acquired by Invitae (NYSE: NVTA). He was Founder | VP of Flex Pharma, IPO (NASDAQ: FLKS). Eric was an EIR at Longwood Fund, and Founder of HBS Angels Boston. He holds a BA from Duke University, and an MBA from Harvard.
Follow Eric Boutin:
About dRx Capital: Novartis Digital Health Venture Capital
Roumen Radinov
Director, Process Chemistry of Alnylam Pharmaceuticals
Follow Roumen Radinov:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Kirk Brown
Director, CNS Early Development of Alnylam Pharmaceuticals
Follow Kirk Brown:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Girija Krishnamurthy
Executive Director Process Development of Amgen
Follow Girija Krishnamurthy:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Girija Krishnamurthy
Executive Director Process Development of Amgen
Follow Girija Krishnamurthy:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Ahmed Alkhateeb
Associate Director of Business Development of Palleon Pharmaceuticals
A molecular biologist with experience in oncology, immunology, and entrepreneurship.
Follow Ahmed Alkhateeb:
About Palleon Pharmaceuticals: Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Nawaz Khan
Research Director, Co-Founder of Discuva
Nawaz Khan is the VP Anti-infectives Research at Summit Therapeutics.
Follow Nawaz Khan:
About Discuva, Summit Therapeutics: Antibacterial discovery research has been driven, medically, commercially
Dan Cowell
Non Executive Director of Sentinel Oncology
Dan has over 15 years’ experience in the contract research and biotechnology industries. He has been involved in ‘hit to lead’ discovery and the investigation of new technologies in the areas of automation, high-throughput catalysis, pharmaceutical solid form and lead generation. Dan was co-founder of Pharmorphix, a specialist CRO in the area of solid form, which grew market share rapidly and was subsequently acquired by Sigma Aldrich in 2006. Following the sale of Pharmorphix he founded Hypoxium, a client focused CRO providing pre-clinical oncology research which grew its revenue at over 75% each year. He was appointed COO of Horizon Discovery following its acquisition in 2010.
Follow Dan Cowell:
About Sentinel Oncology: Sentinel Oncology is a drug discovery company specialising in the delivery of candidate drugs to treat diseases.
Jiahao Huang
Co-founder, Director and CFO of Nuclera
A molecular biologist by trade, Jiahao has coordinated multi-national collaborative projects and experienced first hand the limitations of the current provision of DNA. This intimate knowledge of user requirements enables him to guide Nuclera’s commercial operations towards creating the right product for the right market. Jiahao holds a BSc from the University of California, Berkeley, and a PhD in Molecular Biology from the University of Cambridge.
Follow Jiahao Huang:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Catherine Beech
Board of Directors of Exonate
Follow Catherine Beech:
About : Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.
